Gerd Maass

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

DIB Doblinger Industriebeteiligung GmbH & Co. Holding KG is a private equity firm. The company is based in Munich, Germany.

U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

Medovent GmbH engages in the development and manufacture of medical devices made of the biopolymer chitosan. Its main products are a nerve guide used for peripheral nerve injuries and a direct suture for short nerve defects. The company was founded by Rivelino Montenegro and Thomas Freier in 2006 and is headquartered in Mainz, Germany.

QureInvest AG targets seed and early stage companies located in Germany and Switzerland. It seeks investments in biotechnology and life sciences firms.

Qiagen SRL is engaged in providing assay technologies. The company is headquartered in Milan, Italy.

Verana Health, Inc. engages in the development of software solutions for remote patient monitoring and data analytics. It focuses on bridging the gap between healthcare providers and patients with mobile tests. The company was founded by Mark S. Blumenkranz and Daniel V. Palanker in 2008 and is headquartered in San Francisco, CA.

SightGlass Vision, Inc. is an American clinical-stage life sciences company that focuses on ending nearsightedness in children. The private company is based in California and is developing innovative spectacle lenses based on groundbreaking research from the University of Washington. The company's unique diffusion optics technology is aimed at reducing the progression of myopia in children. SightGlass Vision was founded in 2016 by professors Jay and Maureen Neitz, Dr. James Kuchenbecker, and Dr. Thomas Chalberg, who is the CEO of the company.

Chameleon Biosciences, Inc. engages in the provision of a pre-clinical stage gene therapy. The company was founded by Genine Winslow and Jeffery Scott Vick and is headquartered in Berkeley, CA.

Genascence Corp. develops gene therapy products for musculoskeletal diseases. The company was founded by Dr. Annahita Keravala and Dr. Thomas W. Chalberg in 2017 and is headquartered in Palo Alto, CA.